Dorzolamide (Trusopt)

Dorzolamide, available under the brand name Trusopt, is a topical carbonic anhydrase inhibitor widely used in veterinary ophthalmology to reduce intraocular pressure in cats with glaucoma and ocular hypertension. This medication represents one of the most effective and commonly prescribed topical treatments for feline glaucoma, offering significant pressure-lowering capability when administered as eye drops. Originally developed for human glaucoma management, dorzolamide has become a cornerstone of medical therapy for elevated intraocular pressure in cats, demonstrating reliable efficacy and generally acceptable tolerability in feline patients. Veterinary ophthalmologists frequently include dorzolamide in treatment protocols for both primary and secondary glaucoma.

The mechanism of action of dorzolamide involves selective inhibition of carbonic anhydrase II, an enzyme present in the ciliary body of the eye that plays an essential role in aqueous humor production. By blocking this enzyme, dorzolamide reduces the formation of bicarbonate ions necessary for fluid secretion into the posterior chamber, thereby decreasing the total volume of aqueous humor produced. This reduction in fluid production leads to lower intraocular pressure, helping protect the optic nerve and retina from pressure-induced damage. The targeted mechanism allows dorzolamide to achieve meaningful pressure reduction without the systemic cardiovascular effects associated with some other glaucoma medication classes.

Dorzolamide is formulated as a 2% ophthalmic solution designed for topical administration directly into the affected eye. The medication is typically administered two to three times daily, with specific dosing frequency determined by the veterinary ophthalmologist based on pressure severity and response to treatment. Administration involves placing drops into the conjunctival sac, where the medication is absorbed through the cornea and reaches the ciliary body. The relatively straightforward administration makes dorzolamide accessible for most cat owners, though consistent compliance with multiple daily doses remains essential for optimal pressure control.

Veterinary supervision is essential when using dorzolamide to manage feline glaucoma, as regular monitoring ensures treatment effectiveness and detects any adverse effects or disease progression. Glaucoma is a serious, potentially blinding condition that requires professional management using tonometry to accurately measure intraocular pressure. Your veterinary ophthalmologist will establish baseline pressure measurements, initiate appropriate therapy, and schedule regular rechecks to assess response. While dorzolamide provides important therapeutic benefit, it does not cure glaucoma and typically requires ongoing administration to maintain pressure control. Some cats may eventually need combination therapy or surgical intervention if pressure cannot be adequately controlled with topical medications alone.

The primary indication for dorzolamide in cats is the medical management of glaucoma, a group of conditions characterized by elevated intraocular pressure that threatens vision through damage to the optic nerve and retinal cells. Feline glaucoma represents a significant cause of ocular pain and vision loss, requiring prompt and sustained treatment to preserve sight and comfort. Dorzolamide serves as a first-line topical medication for many feline glaucoma cases, valued for its proven efficacy in reducing intraocular pressure in this species. The medication effectively addresses the fundamental problem of excessive aqueous humor accumulation that drives pressure elevation and subsequent ocular damage.

Secondary glaucoma accounts for the majority of feline glaucoma cases and arises as a complication of other ocular diseases. Anterior uveitis (inflammation inside the eye) represents the most common cause, with inflammatory debris and structural changes obstructing aqueous humor drainage pathways. Other causes include lens luxation, intraocular neoplasia, hyphema (blood in the anterior chamber), and complications from previous ocular surgery or trauma. Dorzolamide helps control pressure in secondary glaucoma cases while concurrent treatment addresses the underlying cause. The medication reduces fluid production regardless of why drainage is impaired, making it useful across various secondary glaucoma etiologies.

Primary glaucoma, while less common in cats than secondary forms, does occur and may have a hereditary component in certain individuals. These cases involve intrinsic abnormalities in the drainage apparatus (iridocorneal angle) that impede aqueous outflow without other inciting disease. Dorzolamide provides pressure control for primary glaucoma patients, though the prognosis for long-term vision preservation varies depending on how early treatment begins and how well pressure responds to medication. Affected cats often require lifelong therapy and may eventually need surgical intervention if medical management becomes insufficient.

Beyond established glaucoma, dorzolamide may be used prophylactically in specific clinical situations. Cats undergoing intraocular surgery may receive perioperative dorzolamide to prevent postoperative pressure spikes that can damage the eye during recovery. In cats with glaucoma affecting one eye, prophylactic treatment of the fellow eye is sometimes considered given the high likelihood of bilateral disease development over time. This prophylactic use remains somewhat controversial, with practices varying among veterinary ophthalmologists based on their interpretation of available evidence and clinical experience.

The selection of dorzolamide for feline glaucoma treatment reflects its favorable efficacy profile in cats compared to some other medication classes. While prostaglandin analogs represent first-line therapy in many human and canine glaucoma cases, their effectiveness in cats is inconsistent and generally inferior. Dorzolamide and other carbonic anhydrase inhibitors have demonstrated more reliable pressure reduction in feline patients, making them preferred choices for topical monotherapy. When additional pressure lowering is needed, dorzolamide combines well with other agent classes in multimodal treatment protocols designed to achieve target pressures through complementary mechanisms.

Dorzolamide dosing for cats typically involves administering one drop of the 2% ophthalmic solution into the affected eye two to three times daily, with the specific frequency determined by your veterinary ophthalmologist based on individual patient needs. More severe pressure elevations may initially require three times daily dosing, while stable, well-controlled cases might be managed with twice daily administration. Your specialist will provide precise instructions and may adjust the dosing schedule based on your cat's response at follow-up examinations. Always follow the prescribed regimen exactly, as consistent administration is essential for maintaining adequate pressure control.

Proper drop administration technique ensures medication reaches the eye effectively while minimizing waste and potential adverse effects. Begin by positioning your cat comfortably and securely, either in your lap or on a stable surface with gentle restraint. Tilt your cat's head slightly upward and use one hand to gently pull down the lower eyelid, creating a small pocket in the conjunctival tissue. With your other hand, hold the dropper bottle above the eye, taking care not to touch the tip to any surface. Squeeze the bottle to release a single drop into the lower conjunctival pocket, then release your cat's eyelid and allow normal blinking to distribute the medication.

After administering dorzolamide, brief punctal occlusion can help reduce systemic absorption and maximize ocular drug concentration. This involves gently pressing on the inner corner of the eye near the nose for approximately one minute after drop instillation. This pressure temporarily blocks the nasolacrimal duct opening, preventing medication from draining into the nasal passages where systemic absorption occurs. While systemic effects from topical dorzolamide are less concerning than with some other glaucoma medications, punctal occlusion represents good practice that may enhance local efficacy.

When multiple ophthalmic medications are prescribed, as is common in glaucoma management, proper timing between different drops is important. Allow at least five to ten minutes between administration of different eye medications. This interval allows adequate absorption of the first medication before the next is applied, preventing dilution or washout effects that could reduce efficacy. Your veterinary ophthalmologist will provide guidance on administration order if timing between drops affects therapeutic outcomes. Keeping a written schedule or setting phone reminders helps maintain consistent timing.

Missed doses should be administered as soon as remembered unless the next scheduled dose is imminent, in which case the missed dose should be skipped and regular timing resumed. Do not double doses to compensate for missed administrations, as this provides no benefit and could increase side effect risk. If you frequently miss doses, discuss strategies with your veterinarian for improving compliance, as irregular treatment significantly compromises pressure control. Some owners find associating drop administration with routine activities (meals, morning coffee, bedtime) helps establish consistent habits.

Treatment duration for glaucoma is typically long-term to lifelong, as the condition cannot be cured with medication alone. Regular monitoring appointments allow your veterinary ophthalmologist to assess pressure control, evaluate for medication side effects, check for disease progression, and adjust the treatment protocol as needed. Initially, rechecks may occur every few weeks until pressure stabilizes; stable patients may transition to monitoring every few months. Never discontinue dorzolamide without veterinary guidance, as stopping treatment allows intraocular pressure to rise, potentially causing rapid and irreversible vision loss.

Dorzolamide is generally well tolerated by most cats when administered as directed, though local ocular effects and occasional systemic reactions can occur. Understanding potential side effects enables prompt recognition and appropriate response, helping maintain your cat's comfort and safety during treatment. Most adverse effects are mild and manageable, but any concerns should be discussed with your veterinary ophthalmologist to determine whether treatment adjustment is needed. Regular monitoring appointments provide opportunities to assess for side effects even before obvious clinical signs develop.

Local ocular irritation represents the most commonly observed side effect of dorzolamide in cats. This may manifest as mild conjunctival redness (hyperemia), increased tearing, or minor ocular discharge. Some cats may show brief squinting or pawing at the eye immediately after drop administration, suggesting stinging or discomfort from the medication. These reactions are typically transient and diminish within minutes of administration. Persistent or worsening ocular irritation warrants veterinary evaluation to distinguish medication effects from disease progression or secondary complications such as corneal ulceration.

Allergic reactions to dorzolamide or its preservatives can develop, though they occur uncommonly. Signs may include pronounced redness, swelling of the eyelids or conjunctiva, increased discharge, or apparent ocular discomfort. These reactions typically develop within the first few weeks of treatment but can occur at any time. If allergic reaction is suspected, contact your veterinary ophthalmologist for guidance on whether to continue treatment and for evaluation of alternative medications. Dorzolamide contains benzalkonium chloride as a preservative, which can cause sensitivity reactions in some patients.

Systemic side effects from topical dorzolamide are possible but less common than with systemic carbonic anhydrase inhibitors. Carbonic anhydrase enzymes exist throughout the body, and if sufficient drug is absorbed systemically, effects on other tissues could theoretically occur. Reported systemic effects in cats are rare but may include gastrointestinal disturbances such as decreased appetite, nausea, or vomiting. Some cats may show lethargy or behavioral changes. The sulfonamide chemical structure of dorzolamide means cats with documented sulfonamide allergies may be at increased risk for adverse reactions.

Serious adverse effects are uncommon but require immediate veterinary attention if observed. Signs warranting urgent care include severe ocular pain (intense squinting, hiding, aggression when head is touched), sudden vision changes, marked swelling of eye or surrounding tissues, severe lethargy or collapse, respiratory difficulties, or any signs of systemic illness. While these severe reactions are rare, their potential seriousness emphasizes the importance of veterinary supervision during dorzolamide therapy. Regular recheck examinations allow your specialist to monitor for early signs of problems and adjust treatment proactively when needed.

Dorzolamide is contraindicated in cats with known hypersensitivity to the medication, its components, or other sulfonamide derivatives. Because dorzolamide belongs to the sulfonamide class of compounds, cats with documented allergies to sulfonamide antibiotics or other sulfonamide-based medications may experience cross-reactive allergic responses. Prior allergic reactions to any sulfonamide drug should be disclosed to your veterinarian before dorzolamide is prescribed. Signs of previous sulfonamide allergy may have included skin reactions, facial swelling, fever, or other hypersensitivity manifestations.

Severe renal impairment represents a relative contraindication for dorzolamide use. The medication undergoes some renal elimination, and significantly reduced kidney function could lead to drug accumulation with potential for increased adverse effects. Cats with chronic kidney disease, a common condition in older feline patients, may require careful evaluation before starting dorzolamide. Your veterinarian will consider kidney function when prescribing and may recommend alternative treatments for cats with advanced renal compromise. Mild to moderate kidney disease does not necessarily preclude dorzolamide use but warrants monitoring.

Significant hepatic dysfunction may also affect dorzolamide handling in the body, as metabolic processes in the liver contribute to drug elimination. Cats with severe liver disease could theoretically experience altered drug metabolism, though clinical significance in feline patients is not well established. Veterinarians consider overall hepatic function when evaluating medication options for individual patients. As with renal concerns, moderate hepatic changes common in older cats do not automatically contraindicate dorzolamide but inform risk-benefit assessment.

Concurrent use of oral carbonic anhydrase inhibitors with topical dorzolamide is generally not recommended due to potential additive effects and increased risk of systemic carbonic anhydrase inhibition. Systemic medications like methazolamide or acetazolamide combined with topical dorzolamide could produce excessive inhibition of carbonic anhydrase throughout the body, leading to metabolic disturbances. If both topical and systemic carbonic anhydrase inhibitors are considered necessary for pressure control, this decision requires careful specialist oversight with appropriate monitoring. Always inform your veterinary ophthalmologist about all medications your cat receives.

Dorzolamide can interact with certain medications, making comprehensive disclosure of all drugs your cat receives essential for safe treatment planning. While significant drug interactions with topical dorzolamide are relatively uncommon in clinical practice, potential exists for both pharmacokinetic interactions affecting drug levels and pharmacodynamic interactions affecting physiological responses. Your veterinary ophthalmologist needs complete medication information to assess interaction risk and design appropriate treatment protocols.

The most notable interaction consideration involves concurrent use of systemic carbonic anhydrase inhibitors with topical dorzolamide. Oral medications such as methazolamide and acetazolamide work through the same mechanism as dorzolamide, and combining topical and systemic carbonic anhydrase inhibitors could produce additive inhibition of carbonic anhydrase enzymes throughout the body. This combination might be intentionally used in refractory glaucoma cases but requires careful monitoring for systemic effects including electrolyte disturbances, metabolic acidosis, and gastrointestinal upset. Such combination therapy falls under specialist management.

High-dose aspirin and other salicylates may theoretically interact with dorzolamide due to competition for renal elimination pathways. While this interaction is more relevant to systemic carbonic anhydrase inhibitor use than topical dorzolamide, it warrants awareness if your cat receives salicylate therapy for any condition. Additionally, dorzolamide's sulfonamide structure means theoretical potential exists for interactions with other sulfonamide-based medications, though clinical significance in cats is not well documented.

When multiple topical ophthalmic medications are used together, as frequently occurs in glaucoma management, appropriate spacing between different drops is important. Administering drops too close together can cause one medication to wash away or dilute another before adequate absorption occurs. Allow at least five to ten minutes between different eye medications. Your veterinary ophthalmologist will provide specific guidance on timing and administration order for your cat's particular medication regimen. Combination products like Cosopt, which contains both dorzolamide and timolol in a single formulation, simplify administration when both medications are indicated.

Regular monitoring by a veterinary ophthalmologist is essential throughout dorzolamide therapy to ensure treatment effectiveness and patient safety. Glaucoma is a serious disease requiring professional management with specialized equipment for accurate intraocular pressure measurement. Home monitoring cannot replace professional tonometry, and treatment adjustments should only occur under veterinary guidance. Schedule and attend all recommended recheck appointments, as early detection of inadequate pressure control or adverse effects enables timely intervention before irreversible damage occurs.

Accurate and consistent medication administration is critical for glaucoma management success. Inconsistent dosing allows intraocular pressure to fluctuate, potentially permitting damage during periods of inadequate control. If you have difficulty administering eye drops to your cat, discuss alternative techniques or formulations with your veterinary ophthalmologist. Some cats tolerate medications better with specific handling approaches, and identifying successful strategies early improves long-term compliance. The consequences of treatment failure in glaucoma are severe, including permanent blindness and chronic ocular pain.

Contamination of the dropper bottle can introduce bacteria into the eye, potentially causing serious infection. Never touch the dropper tip to any surface, including your cat's eye, eyelids, or fur. Keep the cap tightly closed when not in use. If you suspect contamination has occurred, consult your pharmacist or veterinarian about whether the bottle should be replaced. Proper hand hygiene before medication administration further reduces contamination and infection risk.

Special caution applies when using dorzolamide in cats with corneal damage or defects. Corneal ulcers, scratches, or other epithelial defects may allow increased medication penetration into the eye, potentially affecting intraocular tissues beyond the intended ciliary body target. If your cat develops any signs of corneal injury, such as squinting, excessive tearing, cloudiness of the eye surface, or visible defects, contact your veterinary ophthalmologist promptly. The underlying condition may require treatment modification while corneal healing occurs.

Pregnant and nursing cats present special considerations for any medication, including dorzolamide. The effects of topical dorzolamide on feline reproduction, fetal development, and nursing offspring are not well characterized. Systemic carbonic anhydrase inhibitors have shown teratogenic potential in some species, raising theoretical concerns about topical formulations as well. If your cat is pregnant, might become pregnant, or is nursing kittens, discuss these circumstances with your veterinarian. The decision to use dorzolamide in reproductive situations requires careful weighing of maternal glaucoma management needs against potential risks to offspring.

Dorzolamide ophthalmic solution should be stored at controlled room temperature between 59 and 77 degrees Fahrenheit (15 to 25 degrees Celsius), protected from light and excessive heat. Keep the bottle in its original carton when not in use to shield from light exposure. Avoid storing in locations subject to temperature extremes or fluctuations, such as vehicles, windowsills, or near heating and cooling vents. Do not freeze dorzolamide solution, as freezing may affect drug stability and efficacy. Keep the bottle tightly capped between uses to maintain sterility and prevent evaporation.

Proper handling during administration maintains medication sterility and ensures full therapeutic benefit. Wash hands thoroughly with soap and water before handling the medication bottle and administering drops. Avoid touching the dropper tip to any surface, including your fingers, your cat's eye, or surrounding fur and skin. If the dropper tip accidentally contacts any surface, wipe it with a clean tissue without touching the tip itself. Check the solution before each use for any changes in appearance, including color changes, cloudiness, or visible particles. Do not use medication that appears abnormal.

Dispose of dorzolamide properly when treatment is complete or the medication has expired. Do not flush eye drops down the toilet or pour down the drain unless specifically instructed. Many pharmacies and veterinary clinics participate in medication take-back programs that provide safe disposal. If no take-back option is available, mix the medication with an undesirable substance such as used coffee grounds or cat litter, seal in a container, and place in household trash. Remove or obscure personal information on prescription labels before disposal. Keep all medications secured away from children, other pets, and anyone for whom they were not prescribed.

Dorzolamide can be used in cats of all breeds when indicated for glaucoma management, as the medication's efficacy and safety profile do not show significant breed-specific variations. Unlike dogs, where specific breeds carry substantially elevated glaucoma risk due to inherited anatomical features, cats do not display strong breed predispositions to this condition. Most feline glaucoma is secondary to other ocular diseases rather than primary inherited angle abnormalities. Treatment decisions are therefore based primarily on individual patient factors rather than breed considerations.

Burmese cats have been reported in some studies to have higher primary glaucoma incidence compared to other breeds, representing one of the few documented breed associations in feline glaucoma. If your Burmese cat is diagnosed with glaucoma, dorzolamide may be included in the treatment protocol as it would for any other cat. Early diagnosis and consistent treatment remain particularly important in breeds with elevated disease risk, as prompt intervention offers the best chance for vision preservation. Regular ophthalmic examination may be recommended for Burmese cats to enable early detection.

Persian, Himalayan, and other brachycephalic breeds possess facial conformations with prominent eyes that may influence medication administration practicalities. The more exposed eye position in these breeds may actually facilitate drop placement compared to cats with more recessed eyes. However, the prominent globe position also increases exposure to environmental trauma and may affect certain ocular conditions. These anatomical considerations do not alter dorzolamide efficacy or safety but may influence overall eye care approaches in brachycephalic patients.

Individual temperament and handling tolerance vary significantly within breeds and affect treatment compliance more than breed identity itself. Some cats accept eye drop administration calmly while others resist handling regardless of breed background. Building positive associations with the medication routine, using treats and praise, maintaining calm and confident handling, and working in comfortable settings all help improve compliance. If your cat proves particularly challenging for medication administration, discuss strategies with your veterinary team. Successful glaucoma management requires consistent treatment, so identifying effective administration approaches early is important regardless of breed.

Brinzolamide is another topical carbonic anhydrase inhibitor similar to dorzolamide, available under the brand name Azopt. Both medications work through the same mechanism of inhibiting carbonic anhydrase in the ciliary body to reduce aqueous humor production. Brinzolamide is formulated as a suspension rather than a solution and may have a slightly different tolerability profile for some patients. Some cats that experience irritation with dorzolamide may tolerate brinzolamide better, or vice versa, providing an alternative within the same drug class. Your veterinary ophthalmologist may try different carbonic anhydrase inhibitors to optimize the balance of efficacy and tolerability for your cat.

Timolol and other beta-blocker eye drops represent a different medication class used for glaucoma management. These drugs reduce aqueous humor production through beta-adrenergic receptor blockade. Timolol may be used alone or in combination with dorzolamide. A fixed-combination product called Cosopt contains both dorzolamide and timolol, providing dual-mechanism pressure lowering with a single medication and simplified twice-daily administration. This combination is frequently prescribed for feline glaucoma when monotherapy provides insufficient pressure control. Beta-blockers can have systemic cardiovascular effects if absorbed, so they require appropriate monitoring.

Latanoprost and other prostaglandin analogs work by enhancing aqueous humor outflow through the uveoscleral pathway. While highly effective in dogs and humans, prostaglandin analogs have shown inconsistent and often inadequate efficacy in cats. When used in cats, they are typically combined with other medications rather than used as monotherapy. Brimonidine, an alpha-2 adrenergic agonist, provides another mechanism for pressure reduction through both decreased aqueous production and enhanced uveoscleral outflow, though systemic effects require monitoring. Mannitol, administered intravenously, produces rapid pressure reduction in emergencies. Your veterinary ophthalmologist will select appropriate medications based on your cat's specific condition, pressure levels, and response to treatment, potentially using multiple agents in combination for optimal control.